JVS-100: Completed Phase II enrollment

Juventas completed enrollment of 93 patients with ischemic heart failure in the double-blind, placebo-controlled, U.S. Phase II STOP-HF trial evaluating single doses of 15 and 30 mg JVS-100 delivered via endomyocardial injection with the Helical Infusion System from BioCardia Inc. (San Carlos, Calif.). Juventas is also evaluating JVS-100 in the Phase IIa STOP-CLI trial to treat critical limb ischemia (CLI). ...